Gyeonggi-do, South Korea

Hoe Moon Kim

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: C&c Research Laboratories. Active years: 2020.


% Patents Active = 100.0



Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Hoe Moon Kim

Introduction: Hoe Moon Kim is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of heterocyclic derivatives. His work focuses on compounds that have therapeutic potential in treating diseases linked to the activation of specific proteins.

Latest Patents: Hoe Moon Kim holds a patent for "Heterocyclic derivatives and use thereof." This patent describes a heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof. The compound has an inhibitory effect on the activation of the STAT3 protein, making it useful for the prevention or treatment of diseases associated with this protein's activation. He has 1 patent to his name.

Career Highlights: Hoe Moon Kim is affiliated with C&C Research Laboratories, where he continues to innovate and develop new pharmaceutical compounds. His research has the potential to impact the treatment of various diseases, showcasing his commitment to advancing medical science.

Collaborations: Throughout his career, Hoe Moon Kim has worked alongside talented colleagues, including Chan Hee Park and Sang Hwi Lee. Their collaborative efforts contribute to the success of their research initiatives.

Conclusion: Hoe Moon Kim's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in the area of heterocyclic derivatives, highlight the importance of research in developing new treatments for diseases.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…